FDA approves Sarepta’s gene therapy for Duchenne muscular dystrophy

The U.S. Food and Drug Administration has greenlit a gene therapy for Duchenne muscular dystrophy made by Cambridge’s Sarepta Therapeutics Inc. after months of debate over its effectiveness.